Showing results (131-140 of 162) with videos related to

Sort By:
Pageof 17
Gynecologic Oncology|August 23, 2019
PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparibAnna Bianchi, Salvatore Lopez, Gary Altwerger, et al.
Clinical & Experimental Metastasis|June 22, 2024
Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2Levent Mutlu, Blair McNamara, Stefania Bellone, et al.
Gynecologic Oncology|January 7, 2023
Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expressionDennis Mauricio, Stefania Bellone, Levent Mutlu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2024
Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)Sangini S Sheth, Ji Eun Oh, Stefania Bellone, et al.
British Journal of Cancer|February 12, 2022
Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancerDana M Roque, Eric R Siegel, Natalia Buza, et al.
Gynecologic Oncology|November 28, 2022
Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcomaJustin Harold, Stefania Bellone, Diego D Manavella, et al.
Gynecologic Oncology|January 12, 2019
PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancersElena Bonazzoli, Emiliano Cocco, Salvatore Lopez, et al.
Gynecologic Oncology|August 28, 2021
DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivoJoan Tymon-Rosario, Elena Bonazzoli, Stefania Bellone, et al.
Gynecologic Oncology|May 22, 2022
Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitorJoan R Tymon-Rosario, Paola Manara, Diego D Manavella, et al.
Gynecologic Oncology|December 17, 2019
In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinomaChanhee Han, Emanuele Perrone, Burak Zeybek, et al.
Pageof 17